Evidence map›Paper›PMID 33717741›Full record

ArticleCureus2021

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.

Atsuto Katano, Hideomi Yamashita, Keiichi Nakagawa

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Atsuto KatanoRadiology, The University of Tokyo Hospital, Tokyo, JPN.
Hideomi YamashitaRadiology, The University of Tokyo Hospital, Tokyo, JPN.
Keiichi NakagawaRadiology, The University of Tokyo Hospital, Tokyo, JPN.
University of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment effects of metastasis-directed therapy in patients with oligometastatic disease have received much attention. In our case, a 72-year-old man with oligometastatic castration-resistant prostate cancer was referred to our hospital. The patient had undergone radical radiotherapy with a total dose of 76 Gy in 36 fractions for localized prostate cancer nine years prior to the first visit. Positron emission tomography showed a slight increase in accumulation in the para-aortic lymph nodes. The patient received conventional radiotherapy at a total dose of 50 Gy in 25 fractions to the para-aortic region as oligometastasis-directed local therapy. After radiotherapy, his prostate-specific antigen (PSA) level decreased slightly, but it increased again soon after. According to the results of positron emission tomography, the accumulation around the para-aortic lymph nodes had decreased; however, a slight increase in accumulation in the sub/supra-clavicular lymph nodes was observed. He received radiotherapy at a total dose of 50 Gy in 25 fractions to the sub/supra-clavicular region. We confirmed a significant reduction in lesion volume and a downward trend in PSA levels. Metastasis-directed therapy has shown remarkable effectiveness in controlling disease without severe treatment-related adverse events. Metastasis-directed therapy is considered as one of the treatment options in patients who need salvage therapy.

Indexed as

castration-resistant prostate cancermetastasis-directed therapyoligometastasisradiotherapy (rt)recurrence

Identifiers

PMID33717741
PMCPMC7943180
OpenAlexW3129131086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.